NEWS & EVENTS

Latest news and upcoming events

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline
16 Feb 2022

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

Upcoming events

  • ESMO Congress
    9 – 13 September 2022,
    Paris

    download

  • 22nd Annual Biotech in Europe Forum
    21 - 22 September, 2022
    Basel

    download

  • Brain Innovation Days
    11 – 12 October 2022,
    Brussels

    download
Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®<
03 May 2022

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

Expands Commercial coverage to 92% of total commercial lives
SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022<
03 May 2022

SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022

SparingVision, will present pharmacology and safety data on its lead product SPVN06
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting<
03 May 2022

Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Preclinical studies support further development of AU-011 for choroidal metastasis

Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference idal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting<
03 May 2022

Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference idal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

A live webcast of the presentation will be available on Aura's “Investors & Media” page
Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer<
03 May 2022

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small molecules.
Xeltis’ clinical study with restorative hemodialysis access graft, aXess, shows promising early puncturing, patency and safety data<
27 Apr 2022

Xeltis’ clinical study with restorative hemodialysis access graft, aXess, shows promising early puncturing, patency and safety data

International pivotal trial expedited to potentially revolutionize hemodialysis treatment with an immediate and durable solution
LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting<
27 Apr 2022

LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager

400 patients have been enrolled in am-pharma’s pivotal phase 3 study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury<
25 Apr 2022

400 patients have been enrolled in am-pharma’s pivotal phase 3 study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury

Decision from the first pre-specified futility analysis at 400 patients is expected in July
Cvrx reports first quarter 2022 financial and operating results<
25 Apr 2022

Cvrx reports first quarter 2022 financial and operating results

First quarter 2022 revenue of $4.1 million, a 43% increase over prior year
Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting<
11 Apr 2022

Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting

We are encouraged by this data and look forward to further support the ongoing development of a uPARAPtargeting ADC in order to improve the outcome of our patients

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.